Zyrifa Launched: A New Tool to Fight Skeletal Complications in Cancer Patients – Analyzed
Cancer can cause the disease to spread to the bones, leading to serious problems. This is called bone metastasis, and it can weaken bones, cause pain, and make it harder for patients to move around. ‘Zyrifa’, a new medication from Zydus Lifesciences, is designed to help stop these complications from developing.
Key Points
- ‘Zyrifa’ is a copy of a drug used to protect bones.
- It helps prevent bone problems caused by spreading cancer.
- It’s used for cancers like breast, prostate, and lung.
- The cost is Rs 12,495, making it more accessible.
- Patients can maintain mobility and strength during treatment.
- Zydus is expanding its range of medicines to fight cancer.
Understanding Bone Metastasis
When cancer spreads to the bones, it creates a big challenge for people with cancer. The cancer cells start growing in the bone tissue, weakening the bone and making it more likely for the bone to break. This is a serious problem because it can cause significant pain and disability.
What is ‘Zyrifa’?
‘Zyrifa’ is a medicine called Denosumab, which is a type of drug that blocks a specific protein in the body. This protein is involved in breaking down bone tissue. By blocking it, ‘Zyrifa’ helps to stop the cancer from damaging the bones.
Who Can Use ‘Zyrifa’?
‘Zyrifa’ is used for patients who have cancer that has spread to their bones. This includes cancers like breast cancer, prostate cancer, lung cancer, multiple myeloma (a type of blood cancer), kidney cancer, thyroid cancer, and cancers of the head and neck. It’s designed to protect these patients from the harmful effects of bone metastasis.
Zydus Lifesciences’ Commitment
Zydus Lifesciences is already making biosimilars – medicines that are similar to existing drugs – for other types of cancer. They’re working to make these important medicines more affordable and available to patients.
“Our goal is to provide accessible treatment options, enabling patients to maintain their quality of life.” – Dr. Sharvil P. Patel, Zydus Lifesciences.
